OnKure Therapeutics, Inc. (OKUR) stock
OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.58−0.17 (-6.18%)
Close on Nov 17, 2026Market cap $104.48MP/E –Yield –
OnKure Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
OnKure Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $46.95M, down 6.3% year over year. For fiscal 2025 it was $48.26M, up 10.2% from the year before. The highest annual figure on record is $48.26M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.26M | +10.2% |
| FY2024 | Dec 31, 2024 | $43.80M | +36.4% |
| FY2023 | Dec 31, 2023 | $32.12M | -14.8% |
| FY2022 | Dec 31, 2022 | $37.71M | +33.9% |
| FY2021 | Dec 31, 2021 | $28.17M | +76.7% |
| FY2020 | Dec 31, 2020 | $15.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.61M | -0.0% |
| Q1 FY2026 | Mar 31, 2026 | $11.71M | -10.0% |
| Q4 FY2025 | Dec 31, 2025 | $10.72M | -25.4% |
| Q3 FY2025 | Sep 30, 2025 | $11.92M | +17.8% |
| Q2 FY2025 | Jun 30, 2025 | $12.61M | +17.3% |
| Q1 FY2025 | Mar 31, 2025 | $13.01M | +51.9% |
| Q4 FY2024 | Dec 31, 2024 | $14.36M | -18.4% |
| Q3 FY2024 | Sep 30, 2024 | $10.12M | -25.7% |
| Q2 FY2024 | Jun 30, 2024 | $10.75M | -25.3% |
| Q1 FY2024 | Mar 31, 2024 | $8.57M | -22.1% |
| Q4 FY2023 | Dec 31, 2023 | $17.60M | +70.0% |
| Q3 FY2023 | Sep 30, 2023 | $13.62M | +37.1% |
| Q2 FY2023 | Jun 30, 2023 | $14.40M | +77.1% |
| Q1 FY2023 | Mar 31, 2023 | $10.99M | +18.5% |
| Q4 FY2022 | Dec 31, 2022 | $10.36M | +45.9% |
| Q3 FY2022 | Sep 30, 2022 | $9.94M | +6.7% |
| Q2 FY2022 | Jun 30, 2022 | $8.13M | +29.5% |
| Q1 FY2022 | Mar 31, 2022 | $9.28M | +69.6% |
| Q4 FY2021 | Dec 31, 2021 | $7.10M | +38.7% |
| Q3 FY2021 | Sep 30, 2021 | $9.32M | +110.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.28M | +122.9% |
| Q1 FY2021 | Mar 31, 2021 | $5.47M | +52.9% |
| Q4 FY2020 | Dec 31, 2020 | $5.12M | – |
| Q3 FY2020 | Sep 30, 2020 | $4.43M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.82M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.58M | – |
See a number that looks wrong?